Navigation Links
CMC Biologics Strengthens its Innovative Biomanufacturing Technology Portfolio in Continuous Perfusion Systems
Date:1/5/2012

COPENHAGEN, Denmark and SEATTLE, Jan. 5, 2012 /PRNewswire/ -- CMC Biologics, a leading biopharmaceutical contract manufacturing organization, announced the issuance of European Patent No. US 2,171,034 B1 covering a method for improving productivity in microbial fermentations and mammalian cell culture bioreactors. The invention is designed to optimize production of a biotherapeutic in a continuous perfusion fermentation process, wherein the bioreactor (fermenter) has an ultrafiltration system that allows impurities to be removed while retaining cells in the bioreactor.

(Logo:  http://photos.prnewswire.com/prnh/20110502/SF93356LOGO)

"CMC Biologics is continually innovating to advance biopharmaceutical manufacturing to the next level. Our expertise in developing efficient production processes puts our clients' projects in an optimal position to succeed," said Mads Laustsen, Chief Scientific Officer of CMC Biologics and Inventor.  "This proprietary technology demonstrates that using the impurity filter improved cell density, productivity and product concentration – all critical to helping our customers move their products to market on time and on target."

 

Perfusion bioreactors involve continuous cell culture, feeding, and withdrawal (harvesting) of product and accumulates no waste products, thereby creating a stable cell growth environment.  Optimal environmental conditions can be precisely controlled with this new technology resulting in increased productivity due to increased cell density in the reactor and in particular, a significant higher concentration of the product in the harvested medium. The expressed biologics are rapidly removed and made available for purification at high concentration — a significant advantage for the downstream processing.

 

About CMC Biologics

CMC Biologics (www.cmcbio.com) is a global contract biopharmaceutical manufacturing and development organization with facilities in Copenhagen, Denmark and Seattle, Washington, USA. CMC Biologics specializes in custom services for scale up and cGMP manufacture of protein-based therapeutics for preclinical, clinical trials, and in-market production. The Company's fully integrated services includes cell line development using its proprietary CHEF1® system, process and formulation development, and comprehensive analytical testing. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers stirred tank and perfusion production processes.

 

 


 


'/>"/>
SOURCE CMC Biologics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody
2. Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy
3. Therapure Biopharma Inc. announces collaboration with Induce Biologics Inc.
4. Savient Submits Biologics License Application (BLA) for pegloticase
5. DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter
6. Interface Biologics secures $5mm financing and appoints Thomas P. Reeves President and Chief Executive Officer
7. Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
8. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
9. Bone Biologics Announces UCB-1 (NELL-1) Bone Growth Protein Production Process With Aragen Biosciences
10. Frost & Sullivan Recognizes ApaTechs Leadership in Orthopedic Biologics
11. LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016  The Maryland House of ... has announced that University of Maryland School of Medicine ... and University of Maryland Medical System President and CEO ... "Speaker,s Medallion," the highest honor given to the public ... Dean Reece and Mr. Chrencik for ...
(Date:2/10/2016)... New York, and New York, New York (PRWEB) , ... ... ... Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) today announced that it ... and develop new vaccines and immunotherapies for infectious diseases and cancer. ...
(Date:2/10/2016)... 10, 2016  Matchbook, Inc., a company specializing ... biotech companies, announced today the appointment of ... Jim brings nearly 25 years of experience in ... spent nearly two decades in executive level roles ... at Genzyme and, most recently headed global logistics ...
(Date:2/10/2016)... ... February 10, 2016 , ... LATHAM, NEW YORK... Marktech Optoelectronics will ... conference in San Francisco’s Moscone Center from February 16-18, 2016, and at the ... These latest InGaAs PIN diode standard packages feature a TO-46 metal can with active ...
Breaking Biology Technology:
(Date:1/25/2016)... , Jan. 25, 2016  Glencoe Software, the ... pharma and publication industries, will provide the data management ... Centre (NPSC). ... Phenotypic analysis measures ... whole organisms, allowing comparisons between states such as health ...
(Date:1/21/2016)... 21, 2016 --> ... market research report "Emotion Detection and Recognition Market by Technology ... (Facial Expression, Voice Recognition and Others), Services, Application ... to 2020", published by MarketsandMarkets, the global Emotion ... USD 22.65 Billion by 2020, at a CAGR ...
(Date:1/20/2016)... 20, 2016  Synaptics Incorporated (NASDAQ: SYNA ... today announced sampling of S1423, its newest ClearPad ... small screen applications including smartwatches, fitness trackers, and ... and rectangular shapes, as well as thick and ... moisture on screen, while wearing gloves, and supports ...
Breaking Biology News(10 mins):